Alexandra MacLean, Avenue Therapeutics CEO
Avenue touts progress with FDA on embattled pain candidate after two CRLs, failed adcomm
Avenue Therapeutics says it is mostly in agreement with FDA on trial protocols for a potential Phase III safety study, which could lead to the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
